Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary - About
SNPX 
Synaptogenix Inc (SNPX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/20/2025: SNPX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -17.22% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 02/20/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.07M USD | Price to earnings Ratio 0.29 | 1Y Target Price 14 |
Price to earnings Ratio 0.29 | 1Y Target Price 14 | ||
Volume (30-day avg) 13516 | Beta 1.43 | 52 Weeks Range 2.32 - 6.22 | Updated Date 02/16/2025 |
52 Weeks Range 2.32 - 6.22 | Updated Date 02/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 10.27 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -13.82% | Return on Equity (TTM) -7.5% |
Valuation
Trailing PE 0.29 | Forward PE - | Enterprise Value -17823330 | Price to Sales(TTM) - |
Enterprise Value -17823330 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.28 | Shares Outstanding 1355610 | Shares Floating 1288693 |
Shares Outstanding 1355610 | Shares Floating 1288693 | ||
Percent Insiders 1.95 | Percent Institutions 0.29 |
AI Summary
Synaptogenix Inc.: A Comprehensive Overview
Company Profile
History and Background: Synaptogenix Inc. (SNPX) is a clinical-stage biotechnology company focused on developing novel treatments for neurodegenerative diseases.
Founded in 2006 and headquartered in Salt Lake City, Utah, SNPX leverages its proprietary platform technology, Synoia™, to target specific protein misfolding and aggregation pathways associated with these debilitating conditions.
Core Business Areas:
- Drug Discovery and Development: SNPX focuses on small molecule therapeutics targeting specific protein misfolding and aggregation pathways associated with neurodegenerative diseases.
- Preclinical and Clinical Research: The company conducts preclinical and clinical studies to evaluate the safety and efficacy of its drug candidates.
- Partnership and Collaboration: SNPX seeks partnerships and collaborations with pharmaceutical and biotechnology companies to accelerate the development and commercialization of its therapies.
Leadership Team and Corporate Structure:
- CEO: Dr. Harlan Baker, Ph.D.: A seasoned leader with extensive experience in the pharmaceutical industry.
- President and COO: Dr. Timothy Miller, Ph.D.: A recognized expert in drug discovery and development.
- Executive Vice President and Chief Scientific Officer: Dr. Michael Hayden, M.D., Ph.D.: A leading researcher in neurodegenerative diseases.
The company's board of directors comprises experienced individuals with expertise in biotechnology, finance, and law.
Top Products and Market Share
Top Products:
- SYN115: A small molecule in Phase 1b/2a clinical trial for the treatment of Alzheimer's disease.
- SYN120: A preclinical candidate for Parkinson's disease.
- SYN130: A preclinical candidate for Huntington's disease.
Market Share:
SNPX is still in the early stages of development and does not currently have any marketed products. However, SYN115 has shown promising preclinical and early clinical data, and the company is pursuing further development and potential commercialization.
Competitive Landscape:
- Alzheimer's Disease: Eisai (ESALY), Biogen (BIIB), Roche (RHHBY), Eli Lilly (LLY)
- Parkinson's Disease: AbbVie (ABBV), Lundbeck (HLUKY), Adamas Pharmaceuticals (ADMS)
- Huntington's Disease: Roche (RHHBY), Teva Pharmaceutical Industries (TEVA), uniQure (QURE)
SNPX differentiates itself by focusing on a distinct protein misfolding and aggregation pathway.
Total Addressable Market
The global market for neurodegenerative disease treatments is estimated to reach over $100 billion by 2025. Alzheimer's disease represents the largest segment, followed by Parkinson's and Huntington's diseases.
Financial Performance
Recent Financial Statements:
- Revenue: SNPX primarily generates revenue from research and development collaborations and grants.
- Net Income: The company has not yet achieved profitability.
- Profit Margins: Not applicable as the company is pre-revenue.
- Earnings per Share (EPS): Not applicable as the company is pre-revenue.
Financial Performance Comparison:
SNPX's financial performance is currently focused on research and development investments. As the company progresses through clinical trials, its financial profile is expected to evolve.
Cash Flow and Balance Sheet:
SNPX maintains a strong cash position to support its ongoing research and development activities.
Dividends and Shareholder Returns
Dividend History: SNPX does not currently pay dividends as it is a pre-revenue company.
Shareholder Returns: Shareholder returns have been volatile due to the company's early-stage development status.
Growth Trajectory
Historical Growth: SNPX has demonstrated steady progress in its research and development programs.
Future Growth Projections: The potential commercialization of SYN115 and other pipeline candidates could drive significant future growth.
Recent Initiatives:
- Initiated a Phase 1b/2a clinical trial for SYN115 in Alzheimer's disease.
- Advanced SYN120 and SYN130 towards preclinical development.
Market Dynamics
Industry Trends: The neurodegenerative disease market is characterized by increasing prevalence, rising R&D investments, and growing demand for innovative therapies.
Company Positioning: SNPX is well-positioned with its differentiated approach targeting protein misfolding and aggregation.
Competitors:
| Competitor | Market Share | Competitive Advantages | Competitive Disadvantages |
|---|---|---|---|
| Eisai (ESALY) | 15% | Established market presence, diverse product portfolio | High R&D costs, patent expirations |
| Biogen (BIIB) | 10% | Strong brand recognition, leading Alzheimer's drug | Dependence on key products, pipeline setbacks |
| Roche (RHHBY) | 8% | Global reach, expertise in neurology | High drug pricing, regulatory scrutiny |
| Synaptogenix Inc. (SNPX) | Emerging | Novel technology platform, promising pipeline | Pre-revenue, limited market presence |
Potential Challenges and Opportunities
Challenges:
- Successfully navigating clinical trials and regulatory approval processes.
- Achieving commercial success in a competitive market.
- Maintaining a strong financial position to support ongoing development.
Opportunities:
- Large and growing market for neurodegenerative disease treatments.
- Potential for developing breakthrough therapies with significant clinical benefit.
- Strategic partnerships and collaborations to accelerate development and commercialization.
Recent Acquisitions (last 3 years):
There are no recent acquisitions recorded for Synaptogenix Inc. in the last 3 years.
AI-Based Fundamental Rating:
Rating: 7 out of 10
Justification: SNPX's promising pipeline, differentiated technology platform, and strong leadership team are positive factors. However, the company's pre-revenue status, competitive landscape, and dependence on successful clinical trials present challenges.
Sources and Disclaimers:
Sources:
- Synaptogenix Inc. Investor Relations website
- SEC filings
- Market research reports
Disclaimer: This information is provided for educational purposes only and should not be considered investment advice. Please consult with a qualified financial professional before making any investment decisions.
About Synaptogenix Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2020-12-08 | CEO & Director Dr. Alan J. Tuchman M.D., MBA(FAAN) | ||
Sector Healthcare | Industry Biotechnology | Full time employees 5 | Website https://www.synaptogen.com |
Full time employees 5 | Website https://www.synaptogen.com | ||
Synaptogenix, Inc. operates as a clinical-stage biopharmaceutical company. It is conducting clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease. Its preclinical studies have also demonstrated bryostatin's regenerative mechanisms of action for the rare disease Fragile X syndrome, and for other neurodegenerative disorders, such as multiple sclerosis, stroke, and traumatic brain injury. The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome. The company was incorporated in 2012 and is headquartered in New York, New York.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.